Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parasitological confirmation~* at least 1 lesion must be ulcerative~* No specific antileishmanial therapy during the previous six months~Exclusion Criteria:~* Concomitant diseases such as Tuberculosis, HIV, diabetes, renal failure, liver disease~* abnormalities CTC 2 in blood, liver, kidney test or EKG

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Miltefosine and Antimony (Type: EXPERIMENTAL): Miltefosine 1,5 to 2,5 mg x k x d during 14 days simultaneously with meglumine antimoniate 20 mg x kg x d during 10 days
- Miltefosine alone (Type: ACTIVE_COMPARATOR): Miltefosine 1,5 to 2,5 mg x kg x d during 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).